# RealMind Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/realmind-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.realmindbio.com
- Latest round: Series C (Aug 20, 2026)
- Investors on record: 2

## About

Based in Jiangsu, China and founded in 2015, Nanjing RealMind Biotech Co., Ltd., dba RealMind Biotech, is a high-tech enterprise specialized in the R&D, manufacturing and sales of in vitro diagnostic products. The company's founder, Jin Jing, holds a master's degree in biomedical engineering from Southeast University. The company has established partnerships in more than 20 countries spanning Europe, the USA, Latin America, the Middle East, Southeast Asia, and South Asia. 

In August 2026, RealMind Biotech closed a round of Series C funding led by Archaeus Capital, with participation from Amphora Capital.

RealMind Biotech mainly provides fully automatic chemiluminescence analyzers and related reagents, which is based on the direct chemiluminescence method of acridine lipids and supports whole blood detection. The company's products can be applied to clinical testing items such as cardiac markers, inflammation monitoring, reproductive function, growth and development, etc.

The company primarily generates revenue from developing and providing chemiluminescence immunoassay systems and related reagents.

The company will use the Series C funding to expand overseas market presence, accelerate the development of innovative and distinctive projects targeting the elderly and children, continuously strengthen brand, reputation, and product line barriers, promote international expansion, and achieve large-scale, high-quality development.

## Funding rounds

- Series C, Aug 20, 2026 — Amphora Capital, Archaeus Capital

## Investors

- Amphora Capital (https://capitalatlas.ai/funds/amphora-capital) — Series C
- Archaeus Capital (https://capitalatlas.ai/funds/archaeus-capital) — Series C